Trevena
PA - ChesterbrookBiotechnology
Focus: Trevena is a public biotechnology company specializing in GPCR-targeted drug discovery with focus on cardiovascular and neurology therapeutics. The company operates at mid-cap scale with a commercial-stage asset and pipeline programs across pain, heart failure, and migraine indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Trevena
AI assessmentNot HiringNo open roles listed right now. Follow Trevena to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Stable
Peak5.7yr
First and only approved opioid with selective G-protein pathway agonism; represents the company's sole commercial revenue engine with 6-year exclusivity runway.
Help build intelligence for Trevena
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.